Michigan Pathology

Congratulations to #UMichPath researchers, Drs. Jolanta Grembecka and Tomasz Cierpicki on their recent @US_FDA approval of the first once-daily oral therapy for relapsed/refractory NPM1-mutant acute myeloid leukemia.

“This transformative discovery, grounded in research conducted in the Department of Pathology, marks an important moment for our community. The work of Drs. Grembecka and Cierpicki, now recognized through FDA approval, reflect the strength of our scientific environment and our commitment to improving care for patients. It is meaningful to see U-M Pathology contribute to a therapy that is making a real difference for those with leukemia,” said Charles Parkos, Chair of the Department of Pathology.

Read about their work: michmed.org/qNYd4

In the latest episode of Neuro-Oncology, #UMichPath's Dr. Sriram Venneti (@vennetilab) discusses recent advances in ependymoma research.

The conversation explores emerging insights into tumor subtyping, targeted therapies, and the next steps needed to move the field forward.

🎙️ Listen to the episode: michmed.org/W3rdj

The GPALM Summit is right around the corner! Join us by registering here: michmed.org/ZGZXJ.

@UM_cghe

Molecular and Cellular Pathology graduate students have the opportunity to bridge science and business as members of U-M’s miLEAD Consulting. miLEAD connects graduate students and postdocs with real-world consulting projects, helping startups bring innovations to market while building skills beyond the lab. Read about the program: michmed.org/PP25Z
@MCP_Grad_Prog

Meet Huda Rabbani, MD! 🔬 A Michigan native, Dr. Rabbani was drawn to pathology for its mix of scientific discovery, critical thinking, and collaboration. Now beginning her residency at Michigan Medicine, she’s excited to grow as a diagnostician and future educator. michmed.org/rRzYZ